Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

Last updated: September 12, 2023
Sponsor: Far Eastern Memorial Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

tolterodine

tolterodine , mirabegron

mirabegron

Clinical Study ID

NCT05946902
112019-F
  • Ages > 20
  • Female

Study Summary

To evaluate the impact of combined therapy on the heart rate variability, compared with monotherapy in women with overactive bladder syndrome. Secondary objective is to evaluate the impact of combined therapy on bladder blood perfusion.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • >20 years old .
  • female patients with overactive bladder syndrome

Exclusion

Exclusion Criteria:

  • Cases of hypersensitivity to mirabegron or tolterodine.
  • Betanley is contraindicated in the following patients: uncontrolled severehypertension.
  • Dexotol is contraindicated in the following patients: known urethral diverticulum,known bladder malignancy, patients with urinary retention and gastric retention,patients with uncontrolled narrow-angle glaucoma, patients with renal dialysis, severerenal dysfunction (ie Inulin clearance rate (GFR<30 ml/min) or liver dysfunction (i.e.liver cirrhosis), use strong CYP3A4 inhibitors such as ketoconazole.
  • Patients with myasthenia gravis.
  • The patient is taking drugs that interact with tolterodine or mirabegron.

Study Design

Total Participants: 150
Treatment Group(s): 3
Primary Treatment: tolterodine
Phase: 4
Study Start date:
September 12, 2023
Estimated Completion Date:
July 31, 2024

Study Description

Patients and methods:

We will conduct a prospective randomized controlled study in the outpatient clinic of Department of Obstetrics and Gynecology of Far Eastern Memorial Hospital, and will recruit 150 female patients with overactive bladder syndrome. All female patients with overactive bladder syndrome enrolled in the study will be requested to fill in the urgency severity score, the overactive bladder symptom score questionnaire, and the King's health questionnaire before taking the drug and four weeks and twelve weeks after taking the drug. In addition, measurement of heart rate variability and bladder blood perfusion will be performed.

Expected results:

We will obtain the impact of monotherapy with tolterodine or mirabegron versus combined therapy on heart rate variability and bladder blood perfusion in women with overactive bladder syndrome.

Connect with a study center

  • Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital

    Banqiao, New Taipei 22050
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.